These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36706233)

  • 1. Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against
    Stampolaki M; Malwal SR; Alvarez-Cabrera N; Gao Z; Moniruzzaman M; Babii SO; Naziris N; Rey-Cibati A; Valladares-Delgado M; Turcu AL; Baek KH; Phan TN; Lee H; Alcaraz M; Watson S; van der Watt M; Coertzen D; Efstathiou N; Chountoulesi M; Shoen CM; Papanastasiou IP; Brea J; Cynamon MH; Birkholtz LM; Kremer L; No JH; Vázquez S; Benaim G; Demetzos C; Zgurskaya HI; Dick T; Oldfield E; Kolocouris AD
    ACS Infect Dis; 2023 Feb; 9(2):342-364. PubMed ID: 36706233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of SQ109 analogs binding to mycobacterium MmpL3 transporter using MD simulations and alchemical relative binding free energy calculations.
    Stampolaki M; Stylianakis I; Zgurskaya HI; Kolocouris A
    J Comput Aided Mol Des; 2023 Jun; 37(5-6):245-264. PubMed ID: 37129848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure,
    Malwal SR; Zimmerman MD; Alvarez N; Sarathy JP; Dartois V; Nacy CA; Oldfield E
    ACS Infect Dis; 2021 Aug; 7(8):2492-2507. PubMed ID: 34279904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in
    Raynaud C; Daher W; Johansen MD; Roquet-Banères F; Blaise M; Onajole OK; Kozikowski AP; Herrmann JL; Dziadek J; Gobis K; Kremer L
    ACS Infect Dis; 2020 Feb; 6(2):324-337. PubMed ID: 31860799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A piperidinol-containing molecule is active against
    Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
    J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
    [No Abstract]   [Full Text] [Related]  

  • 6. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis.
    Tahlan K; Wilson R; Kastrinsky DB; Arora K; Nair V; Fischer E; Barnes SW; Walker JR; Alland D; Barry CE; Boshoff HI
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1797-809. PubMed ID: 22252828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
    Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HC2091 Kills Mycobacterium tuberculosis by Targeting the MmpL3 Mycolic Acid Transporter.
    Zheng H; Williams JT; Coulson GB; Haiderer ER; Abramovitch RB
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1
    Korycka-Machała M; Viljoen A; Pawełczyk J; Borówka P; Dziadek B; Gobis K; Brzostek A; Kawka M; Blaise M; Strapagiel D; Kremer L; Dziadek J
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.
    Li W; Upadhyay A; Fontes FL; North EJ; Wang Y; Crans DC; Grzegorzewicz AE; Jones V; Franzblau SG; Lee RE; Crick DC; Jackson M
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6413-23. PubMed ID: 25136022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation into the Mechanism of Action of the Tuberculosis Drug Candidate SQ109 and Its Metabolites and Analogues in Mycobacteria.
    Malwal SR; Mazurek B; Ko J; Xie P; Barnes C; Varvitsiotis C; Zimmerman MD; Olatunji S; Lee J; Xie M; Sarathy J; Caffrey M; Strynadka NCJ; Dartois V; Dick T; Lee BNR; Russell DG; Oldfield E
    J Med Chem; 2023 Jun; 66(11):7553-7569. PubMed ID: 37235809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria.
    Fay A; Czudnochowski N; Rock JM; Johnson JR; Krogan NJ; Rosenberg O; Glickman MS
    mBio; 2019 Jun; 10(3):. PubMed ID: 31239378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Efficacy of SQ109 against
    Baek KH; Phan TN; Malwal SR; Lee H; Li ZH; Moreno SNJ; Oldfield E; No JH
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors.
    McNeil MB; O'Malley T; Dennison D; Shelton CD; Sunde B; Parish T
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33055263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in MmpL3 alter membrane potential, hydrophobicity and antibiotic susceptibility in Mycobacterium smegmatis.
    McNeil MB; Dennison D; Parish T
    Microbiology (Reading); 2017 Jul; 163(7):1065-1070. PubMed ID: 28703701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multitarget drug discovery for tuberculosis and other infectious diseases.
    Li K; Schurig-Briccio LA; Feng X; Upadhyay A; Pujari V; Lechartier B; Fontes FL; Yang H; Rao G; Zhu W; Gulati A; No JH; Cintra G; Bogue S; Liu YL; Molohon K; Orlean P; Mitchell DA; Freitas-Junior L; Ren F; Sun H; Jiang T; Li Y; Guo RT; Cole ST; Gennis RB; Crick DC; Oldfield E
    J Med Chem; 2014 Apr; 57(7):3126-39. PubMed ID: 24568559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature.
    Imran M; Arora MK; Chaudhary A; Khan SA; Kamal M; Alshammari MM; Alharbi RM; Althomali NA; Alzimam IM; Alshammari AA; Alharbi BH; Alshengeti A; Alsaleh AA; Alqahtani SA; Rabaan AA
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors.
    Li K; Wang Y; Yang G; Byun S; Rao G; Shoen C; Yang H; Gulati A; Crick DC; Cynamon M; Huang G; Docampo R; No JH; Oldfield E
    ACS Infect Dis; 2015 May; 1(5):215-221. PubMed ID: 26258172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections.
    North EJ; Schwartz CP; Zgurskaya HI; Jackson M
    Expert Opin Drug Discov; 2023 Jul; 18(7):707-724. PubMed ID: 37226498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diphenylether-Modified 1,2-Diamines with Improved Drug Properties for Development against Mycobacterium tuberculosis.
    Foss MH; Pou S; Davidson PM; Dunaj JL; Winter RW; Pou S; Licon MH; Doh JK; Li Y; Kelly JX; Dodean RA; Koop DR; Riscoe MK; Purdy GE
    ACS Infect Dis; 2016 Jul; 2(7):500-8. PubMed ID: 27626102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.